COLUMVI DIN 02536552
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Available to quote
Health Canada record
| Active ingredient(s) | GLOFITAMAB 2.5 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L01FX28 GLOFITAMAB |
|---|
| Original market date | 05-Jul-2023 |
|---|
| Current status date | 05-Jul-2023 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GLOFITAMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02536560 | COLUMVI | HOFFMANN-LA ROCHE LIMITED | Solution | GLOFITAMAB 10 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 30384 | 2023-03-24 | New Drug Submission (NDS) | |
Request a quote for COLUMVI
How to read a Canadian DIN record